Report LibraryAll Reports
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)*Included free with BioMedTracker Subscription - click here to log in
October 09, 2018From the beginning of this decade, immuno-oncology (IO) therapies have begun to change the way a large number of cancers are treated, with greatly improved patient outcomes. On a basic level, IO therapies improve the body’s ability to generate an immune response against cancer, whether by counteracting some of the mechanisms that the tumor uses to suppress the immune system, or facilitating an immune response via introducing tumor-specific antigens. This can be achieved in a variety of ways, with six discrete classes approved thus far, although the programmed death-1 (PD-1)/ligand 1 (L1) inhibitor class has emerged as the most successful.
At Pharma Intelligence, the cutting-edge data, research, analysis, and forecasting you’ve come to expect from Informa’s global business intelligence brands are brought together into a single portfolio. This report includes data and analysis from our leading brands. For more information, please visit pharmaintelligence.informa.com.
|Indications Covered:||Non-Small Cell Lung Cancer (NSCLC)|